Infringement of Third Party Patents. If, as a result of any claim, proceeding or litigation by any Third Party against Signal regarding Signal's proprietary whole-cell and enzyme assays occurring during the term of this Agreement, Signal or Tanabe is barred from carrying out its future material obligations herein, Tanabe has a right to terminate the Collaborative Project.
Appears in 3 contracts
Sources: Collaborative Development and Licensing Agreement (Signal Pharmaceuticals Inc), Collaborative Development and Licensing Agreement (Signal Pharmaceuticals Inc), Collaborative Development and Licensing Agreement (Signal Pharmaceuticals Inc)